睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07410559,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Histologically confirmed invasive ER+/HER2- breast cancer, meeting ER≥50% and Ki67≥10%. HER2 negativity is defined as HER2 immunohistochemistry (IHC) 0-1+, or IHC 2+ with fluorescence in situ hybridization (FISH) confirming no amplification.

    入选标准第 4 条

  3. Clinical tumor stage: cT1c-T4, cN0-cN2, cM0.

    入选标准第 5 条

  4. Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s).

    入选标准第 21 条

    Any prior chemotherapy, endocrine therapy, or anti-HER2 therapy for breast cancer; or prior excisional biopsy of the primary breast tumor and/or axillary lymph nodes, or prior local radiotherapy (excluding diagnostic biopsy for primary breast cancer or surgery for benign breast tumors).

    排除标准第 4 条

    Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment.

    排除标准第 9 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 2 条

  6. Absolute neutrophil count (ANC)≥1.5×10\^9/L;

    入选标准第 9 条

    Platelet count (PLT)≥100×10\^9/L;

    入选标准第 10 条

    Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN) and patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted;

    入选标准第 11 条

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN;

    入选标准第 12 条

    Alkaline phosphatase (ALP)≤2.5×ULN;

    入选标准第 13 条

    Serum creatinine (Cr)≤1.5×ULN;

    入选标准第 14 条

    Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation).

    入选标准第 15 条

  7. Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer.

    排除标准第 5 条

    Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease.

    排除标准第 10 条

  8. Pregnant or breastfeeding.

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07410559,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female patients aged 18 to 75 years.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  3. Primary breast tumor diameter > 1 cm.
  4. Histologically confirmed invasive ER+/HER2- breast cancer, meeting ER≥50% and Ki67≥10%. HER2 negativity is defined as HER2 immunohistochemistry (IHC) 0-1+, or IHC 2+ with fluorescence in situ hybridization (FISH) confirming no amplification.
  5. Clinical tumor stage: cT1c-T4, cN0-cN2, cM0.
  6. Willing to undergo breast cancer surgery once surgical criteria are met after neoadjuvant therapy.
  7. Adequate organ function, meeting all of the following:
  8. Hemoglobin (Hb)≥90 g/L and patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion;
  9. Absolute neutrophil count (ANC)≥1.5×10\^9/L;
  10. Platelet count (PLT)≥100×10\^9/L;
  11. Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN) and patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted;
  12. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN;
  13. Alkaline phosphatase (ALP)≤2.5×ULN;
  14. Serum creatinine (Cr)≤1.5×ULN;
  15. Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation).
  16. Left ventricular ejection fraction (LVEF)≥55% at baseline as measured by echocardiography or multi-gated acquisition (MUGA) scan.
  17. Women with premenopausal status should receive ovarian suppression with a gonadotropin-releasing hormone agonist such as goserelin or leuprolide before initiation of treatment to become postmenopausal status. Postmenopausal due to surgical/natural menopause requires at least 1 of the following:
  18. prior bilateral oophorectomy;
  19. age≥60 years;
  20. age<60 years, amenorrheic for at least 12 months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression), and FSH and estradiol levels in the postmenopausal range.
  21. Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s).
  22. The subject voluntarily agrees to participate, signs the informed consent form, has good compliance, and is willing to adhere to follow-up.

排除标准:Exclusion Criteria:

  1. Stage IV (metastatic) breast cancer or bilateral breast cancer.
  2. Prior history of invasive breast cancer.
  3. Prior history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).
  4. Any prior chemotherapy, endocrine therapy, or anti-HER2 therapy for breast cancer; or prior excisional biopsy of the primary breast tumor and/or axillary lymph nodes, or prior local radiotherapy (excluding diagnostic biopsy for primary breast cancer or surgery for benign breast tumors).
  5. Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer.
  6. Peripheral neuropathy≥Grade 2 per NCI-CTCAE v6.0.
  7. Serious cardiovascular or cerebrovascular disease within 6 months prior to randomization, including but not limited to congestive heart failure, unstable angina, severe arrhythmias uncontrolled by medication, severe conduction abnormalities or clinically significant valvular disease, uncontrolled severe hypertension, myocardial infarction, or cerebrovascular accident.
  8. Any serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  9. Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment.
  10. Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease.
  11. Severe and uncontrolled infection or known HIV infection.
  12. Active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment) or fungal infection.
  13. Pregnant or breastfeeding.
  14. Known allergy to the study drug or any of its excipients, or a history of severe hypersensitivity reactions to other monoclonal antibodies.
  15. Known abuse of psychotropic substances, alcoholism, or drug abuse.
  16. Known, definite neurological or psychiatric disorders associated with poor compliance, including but not limited to epilepsy or dementia.
  17. Any other serious physical or mental illness or laboratory abnormality that may increase the risk of study participation or interfere with study treatment and outcomes, or any other condition that, in the investigator's judgment, makes the patient unsuitable for this study.
  18. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization, or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study.

引自 ClinicalTrials.gov, NCT07410559, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07410559,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07410559